Cybin obtains exclusive license to a novel catalog of psychedelic-based compounds

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biopharmaceutical company focused on progressing psychedelics to therapeutics™, is pleased to announce that, through its wholly-owned subsidiary cybin irl limited, it has entered into an agreement with mindset pharma inc. (cse: mset) (fse: 9df) (otcqb: msstf) (“mindset”) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules from mindset (the “agreement”). pur
CYBN Ratings Summary
CYBN Quant Ranking